• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AAD 2025: Advancements in Dermatology

home / post-conference-perspectives / aad-2025-advancements-in-dermatology

Paul Yamauchi, MD, PhD, discusses recent findings presented at the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) on tildrakizumab’s efficacy for nail psoriasis, biological treatment patterns in moderate to severe psoriasis, ruxolitinib cream’s role in reducing additional medication use in atopic dermatitis, comparative infection risks between Janus kinase and cytokine inhibitors, and the evolution toward personalized dermatological treatment approaches that balance efficacy with safety considerations.

© 2025 MJH Life Sciences
AJMC®
All rights reserved.